| PCI术后患者瑞舒伐他汀联合依折麦布的临床疗效观察 |
| |
| 引用本文： | 封欣妤,王善杰,董媛,孙冬冬,赵志敬. PCI术后患者瑞舒伐他汀联合依折麦布的临床疗效观察[J]. 心脏杂志, 2019, 31(3): 289-294. DOI: 10.12125/j.chj.201810074 |
| |
| 作者姓名： | 封欣妤 王善杰 董媛 孙冬冬 赵志敬 |
| |
| 作者单位： | 1.空军军医大学西京医院心内科，陕西 西安 710032 |
| |
| 摘 要： | 目的 探讨经皮冠状动脉介入(PCI)术后不同降脂方案对血脂及安全性的影响。方法 选取空军军医大学附属西京医院2018年1月~2018年7月拟行PCI的患者104例为研究对象,采用随机数字表法将其随机分为瑞舒伐他汀10mg组(n=35),瑞舒伐他汀20mg组(n=35)和瑞舒伐他汀10mg+依折麦布组(联合用药组,n=34),随访6个月测定三组治疗前后血脂的变化水平,比较3组血脂达标率及用药不良反应发生情况。结果 3组患者治疗后总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、氧化低敏度脂蛋白胆固醇(oxLDL-C)、oxLDL-C/TC、oxLDL-C/LDL-C、oxLDL-C/HDL-C水平明显低于治疗前,差异有统计学意义(均P<0.05);联合用药组上述血脂指标降低幅度均大于瑞舒伐他汀10mg组和20mg组,差异有统计学意义(均P<0.05);联合用药组血脂达标率高于瑞舒伐他汀10mg组和20mg组,差异有统计学意义(均P<0.05);3组的不良反应发生率差异无统计学意义。结论 PCI术后瑞舒伐他汀联合依折麦布有较好的调脂效果、抗氧化作用,血脂达标率较高,且用药安全。
|
| 关 键 词： | 冠状动脉疾病 瑞舒伐他汀 依折麦布 调脂治疗 经皮冠状动脉介入术 |
| 收稿时间： | 2018-10-26 |
Comparison of effects of different lipid-lowering regimens on oxidized low-density lipoprotein and its ratio after PCI |
| |
| FENG Xin-yu,WANG Shan-jie,DONG Yuan,SUN Dong-dong,ZHAO Zhi-jing. Comparison of effects of different lipid-lowering regimens on oxidized low-density lipoprotein and its ratio after PCI[J]. Chinese Heart Journal, 2019, 31(3): 289-294. DOI: 10.12125/j.chj.201810074 |
| |
| Authors: | FENG Xin-yu WANG Shan-jie DONG Yuan SUN Dong-dong ZHAO Zhi-jing |
| |
| Affiliation: | 1.Department of Cardiology, Xijing Hospital, Air Force Medical University, Xi’an 710032, Shaanxi, China2.Department of Cardiology, Second Affiliated Hospital, Harbin Medical University, Harbin 150086, Heilongjiang, China |
| |
| Abstract: | AIM To evaluate clinical efficacy and safety of different lipid-lowering regimens in patients after percutaneous coronary intervention (PCI). METHODS From January 2018 to July 2018, 104 patients with PCI planned were selected as study subjects and were randomly divided into a 10 mg rosuvastatin treatment group (n = 35), a 20 mg rosuvastatin treatment group (n = 35), and a 10 mg rosuvastatin +10 mg ezetimibe combined treatment group (n = 34). The patients were followed up for six months. Serum lipids were measured before and after treatment and compliance rate and adverse drug reactions were compared between the three groups. RESULTS Levels of TC, LDL-C, oxLDL-C, oxLDL-C/TC, oxLDL-C/LDL-C and oxLDL-C/HDL-C were significantly lower than before in the three groups after treatment (P < 0.05). The extent of reduction of TC and LDL-C in the combined 10 mg rosuvastatin + ezetimibe group was significantly larger than those in the 10 mg rosuvastatin and 20 mg rosuvastatin groups (P < 0.05). The rate of attaining the standard of serum lipid in the combined 10 mg rosuvastatin +ezetimibe group was higher than those in the 10 mg rosuvastatin and 20 mg rosuvastatin groups, with statistically significant differences (P < 0.05). There was no statistically significant difference in the incidence of adverse reactions between the three groups (P < 0.05). CONCLUSION The administration of rosuvastatin or the combined administration of rosuvastatin and ezetimibe in patients after percutaneous coronary intervention is safe and achieves beneficial effects in regulation of lipids and antioxidants and in attaining the standard of serum lipids. |
| |
| Keywords: | coronary disease rosuvastatin ezetimibe oxidized-densinity lipoprotein lipid loweringtherapy |
| 本文献已被 CNKI 维普 等数据库收录！ |
| 点击此处可从《心脏杂志》浏览原始摘要信息 |
|
点击此处可从《心脏杂志》下载免费的PDF全文 |
|
